These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 34347960)

  • 1. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.
    Mougiakakos D; Krönke G; Völkl S; Kretschmann S; Aigner M; Kharboutli S; Böltz S; Manger B; Mackensen A; Schett G
    N Engl J Med; 2021 Aug; 385(6):567-569. PubMed ID: 34347960
    [No Abstract]   [Full Text] [Related]  

  • 2. CAR T-Cell Therapy in Autoimmune Disease.
    Howard JF; Vu T; Mozaffar T
    N Engl J Med; 2024 May; 390(17):1629-1631. PubMed ID: 38692299
    [No Abstract]   [Full Text] [Related]  

  • 3. CAR T-Cell Therapy in Autoimmune Disease.
    Merkt W; Lorenz HM; Schmitt M
    N Engl J Med; 2024 May; 390(17):1628-1629. PubMed ID: 38692297
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
    Mackensen A; Müller F; Mougiakakos D; Böltz S; Wilhelm A; Aigner M; Völkl S; Simon D; Kleyer A; Munoz L; Kretschmann S; Kharboutli S; Gary R; Reimann H; Rösler W; Uderhardt S; Bang H; Herrmann M; Ekici AB; Buettner C; Habenicht KM; Winkler TH; Krönke G; Schett G
    Nat Med; 2022 Oct; 28(10):2124-2132. PubMed ID: 36109639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T-Cell Therapy in Autoimmune Disease.
    De Benedetti F; Diomedi Camassei F; Locatelli F
    N Engl J Med; 2024 May; 390(17):1629. PubMed ID: 38692298
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE.
    Li M; Zhang Y; Jiang N; Ning C; Wang Q; Xu D; Wang Z; Lv L; Zhou D; Zeng X
    N Engl J Med; 2024 Jul; 391(4):376-378. PubMed ID: 39047248
    [No Abstract]   [Full Text] [Related]  

  • 7. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview.
    Abdalhadi HM; Chatham WW; Alduraibi FK
    Int J Mol Sci; 2024 Sep; 25(19):. PubMed ID: 39408836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.
    Kansal R; Richardson N; Neeli I; Khawaja S; Chamberlain D; Ghani M; Ghani QU; Balazs L; Beranova-Giorgianni S; Giorgianni F; Kochenderfer JN; Marion T; Albritton LM; Radic M
    Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T-cell therapy in autoimmune diseases.
    Schett G; Mackensen A; Mougiakakos D
    Lancet; 2023 Nov; 402(10416):2034-2044. PubMed ID: 37748491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
    Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of SLE with anti-CD19 CAR-T cells.
    Carney EF
    Nat Rev Nephrol; 2022 Dec; 18(12):743. PubMed ID: 36323874
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
    Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
    Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-T cell therapy: new hope for systemic lupus erythematosus patients.
    Jin X; Han Y; Wang JQ; Lu L
    Cell Mol Immunol; 2021 Dec; 18(12):2581-2582. PubMed ID: 34737415
    [No Abstract]   [Full Text] [Related]  

  • 16. Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment.
    Kambayana G; Surya Rini S
    Curr Rheumatol Rev; 2023 Jun; 19(3):260-269. PubMed ID: 36786138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
    Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
    Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy.
    Guffroy A; Jacquel L; Guffroy B; Martin T
    Joint Bone Spine; 2024 Sep; 91(5):105702. PubMed ID: 38336271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.